Cyclerion Therapeutics Inc.

0.9800+0.0200+2.08%Vol 152.05K1Y Perf -71.08%
Aug 11th, 2022 15:48 DELAYED
BID0.9422 ASK0.9800
Open0.9600 Previous Close0.9600
Pre-Market- After-Market-
 - -  - -%
Target Price
9.00 
Analyst Rating
Strong Buy 1.00
Potential %
818.37 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     50.42
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
16.41 
Earnings Rating
Market Cap42.61M 
Earnings Date
11th Aug 2022
Alpha-0.04 Standard Deviation0.32
Beta1.79 

Today's Price Range

0.93001.03

52W Range

0.46133.62

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
8.88%
1 Month
19.53%
3 Months
67.95%
6 Months
-19.01%
1 Year
-71.08%
3 Years
-88.22%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CYCN0.98000.02002.08
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 470.60
-1 463.00
-
-
RevenueValueIndustryS&P 500US Markets
483.00K
0.01
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.34-0.318.82
Q01 2022-0.36-0.3016.67
Q04 2021-0.32-0.2425.00
Q03 2021-0.29-0.2610.34
Q03 2020--0.59-
Q02 2020--0.70-
Q01 2020--0.73-
Q04 2019--0.95-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.34
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume152.05K
Shares Outstanding43.48K
Shares Float33.09M
Trades Count265
Dollar Volume147.96K
Avg. Volume245.97K
Avg. Weekly Volume295.61K
Avg. Monthly Volume167.79K
Avg. Quarterly Volume274.52K

Cyclerion Therapeutics Inc. (NASDAQ: CYCN) stock closed at 0.98 per share at the end of the most recent trading day (a 2.08% change compared to the prior day closing price) with a volume of 152.05K shares and market capitalization of 42.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 34 people. Cyclerion Therapeutics Inc. CEO is Peter M. Hecht.

The one-year performance of Cyclerion Therapeutics Inc. stock is -71.08%, while year-to-date (YTD) performance is -43.02%. CYCN stock has a five-year performance of %. Its 52-week range is between 0.4613 and 3.6225, which gives CYCN stock a 52-week price range ratio of 16.41%

Cyclerion Therapeutics Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 1.06, a price-to-sale (PS) ratio of 75.13, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.94%, a ROC of -119.87% and a ROE of -119.87%. The company’s profit margin is -%, its EBITDA margin is -1 463.00%, and its revenue ttm is $483.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Cyclerion Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Cyclerion Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cyclerion Therapeutics Inc. is Strong Buy (1), with a target price of $9, which is +818.37% compared to the current price. The earnings rating for Cyclerion Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclerion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclerion Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.71, ATR14 : 0.13, CCI20 : 94.04, Chaikin Money Flow : 0.02, MACD : 0.07, Money Flow Index : 43.10, ROC : 23.87, RSI : 58.06, STOCH (14,3) : 49.10, STOCH RSI : 0.03, UO : 51.26, Williams %R : -50.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclerion Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

CEO: Peter M. Hecht

Telephone: +1 857 327-8778

Address: 301 Binney Street, Cambridge 02142, MA, US

Number of employees: 34

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

72%28%

Bearish Bullish

58%42%


News

Stocktwits